Patents by Inventor Patricia René
Patricia René has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11246331Abstract: The invention relates to small edible portions (i.e., bite-sized snacks) comprising a soft nut butter inner core coated with a crunchy grain-based outer coating. The bite-sized snacks have an equivalent spherical diameter of about 1 to 3 cm. Texture analysis of the bite-sized snacks determines that the bite-sized snacks have a soft texture with an average peak force in the range of about 800-5,000 g and an average positive area in the range of about 2,000-15,000 g*sec. The bite-sized snacks unexpected have both a soft and crunchy texture and are surprisingly shelf stable.Type: GrantFiled: June 15, 2018Date of Patent: February 15, 2022Assignee: THE J. M. SMUCKER COMPANYInventors: Andrea Wunder Shoop, Nathaniel David Kennedy, Patricia Rene Wireman
-
Publication number: 20180368452Abstract: The invention relates to small edible portions (i.e., bite-sized snacks) comprising a soft nut butter inner core coated with a crunchy grain-based outer coating. The bite-sized snacks have an equivalent spherical diameter of about 1 to 3 cm. Texture analysis of the bite-sized snacks determines that the bite-sized snacks have a soft texture with an average peak force in the range of about 800-5,000 g and an average positive area in the range of about 2,000-15,000 g*sec. The bite-sized snacks unexpected have both a soft and crunchy texture and are surprisingly shelf stable.Type: ApplicationFiled: June 15, 2018Publication date: December 27, 2018Applicant: THE J. M. SMUCKER COMPANYInventors: Andrea Wunder Shoop, Nathaniel David Kennedy, Patricia Rene Wireman
-
Patent number: 9937165Abstract: The invention relates to methods of enhancing normal melanocortin-4 receptor (MC4R) activity, and to enhancing activity of an MC4R having a mutation which affects protein folding and/or processing of the MC4R. The invention provides a method of treating an individual having a condition in which increased activity of an MC4R at the cell surface would be beneficial, for example in obesity, by administering an effective amount of a pharmacological chaperone for the MC4R. The invention provides MC4R pharmacological chaperones which enhance the activity of MC4R. The invention further provides a method of screening to identify pharmacological chaperones which enhance folding of an MC4R in the endoplasmic reticulum (ER), in order to enhance the activity of the MC4R at the cell surface.Type: GrantFiled: May 6, 2016Date of Patent: April 10, 2018Assignees: Amicus Therapeutics, Inc., Universite de MontrealInventors: Jian-Qiang Fan, Kenneth Valenzano, Gary Lee, Michel Bouvier, Patricia René
-
Publication number: 20160345553Abstract: There are provided herein transgenic non-human animals and cells comprising a transgene encoding either a mutated human melanocortin type-4 receptor (hMC4R) protein, wherein the mutated protein is misfolded and retained intracellularly, or a wild-type human melanocortin type-4 receptor (hMC4R) protein. Transgenes and targeting constructs used to produce such transgenic animals and cells are also provided, as well as methods for using the transgenic animals in pharmaceutical screening and as commercial research animals for modeling obesity.Type: ApplicationFiled: August 12, 2016Publication date: December 1, 2016Applicant: UNIVERSITE DE MONTREALInventors: Michel BOUVIER, Patricia RENE, Benjamin TURGEON
-
Patent number: 9493456Abstract: Disclosed herein is a compound of Formula I: wherein X, R1, R2, and R3 are as defined herein, or a pharmaceutically acceptable salt thereof to allow the drug to penetrate the cell membrane; or a prodrug, or the compound is labeled with a detectable label or an affinity tag thereof. Also disclosed is a pharmaceutical composition, a method of treating a disorder mediated by melanocortin-4 receptors, and a method of treating obesity using the compounds described.Type: GrantFiled: March 26, 2015Date of Patent: November 15, 2016Assignee: UNIVERSITE DE MONTREALInventors: Michel Bouvier, Anne Marinier, Réjean Ruel, Patricia René, Yves Chantigny, Philippe Dagneau, Stéphane Gingras
-
Publication number: 20160296507Abstract: Disclosed is a compound of Formula I: or a salt thereof, in which X, X1, X2, R1, R2, and R3 are described herein. Also disclosed are pharmaceutical compositions and methods of using the compounds of Formula I to treat disorders mediated by melanocortin-4 receptors.Type: ApplicationFiled: June 21, 2016Publication date: October 13, 2016Applicant: UNIVERSITE DE MONTREALInventors: Réjean RUEL, Yves CHANTIGNY, Anne MARINIER, Patricia RENE, Michel BOUVIER
-
Publication number: 20160287581Abstract: The invention relates to methods of enhancing normal melanocortin-4 receptor (MC4R) activity, and to enhancing activity of an MC4R having a mutation which affects protein folding and/or processing of the MC4R. The invention provides a method of treating an individual having a condition in which increased activity of an MC4R at the cell surface would be beneficial, for example in obesity, by administering an effective amount of a pharmacological chaperone for the MC4R. The invention provides MC4R pharmacological chaperones which enhance the activity of MC4R. The invention further provides a method of screening to identify pharmacological chaperones which enhance folding of an MC4R in the endoplasmic reticulum (ER), in order to enhance the activity of the MC4R at the cell surface.Type: ApplicationFiled: May 6, 2016Publication date: October 6, 2016Inventors: Jian-Qiang Fan, Kenneth Valenzano, Gary Lee, Michel Bouvier, Patricia René
-
Patent number: 9381194Abstract: The invention relates to methods of enhancing normal melanocortin-4 receptor (MC4R) activity, and to enhancing activity of an MC4R having a mutation which affects protein folding and/or processing of the MC4R. The invention provides a method of treating an individual having a condition in which increased activity of an MC4R at the cell surface would be beneficial, for example in obesity, by administering an effective amount of a pharmacological chaperone for the MC4R. The invention provides MC4R pharmacological chaperones which enhance the activity of MC4R. The invention further provides a method of screening to identify pharmacological chaperones which enhance folding of an MC4R in the endoplasmic reticulum (ER), in order to enhance the activity of the MC4R at the cell surface.Type: GrantFiled: August 3, 2009Date of Patent: July 5, 2016Assignee: Amicus Therapeutics, Inc.Inventors: Jian-Qiang Fan, Kenneth Valenzano, Gary Lee, Michel Bouvier, Patricia René
-
Publication number: 20150197520Abstract: Disclosed herein is a compound of Formula I: wherein X, R1, R2, and R3 are as defined herein, or a pharmaceutically acceptable salt thereof to allow the drug to penetrate the cell membrane; or a prodrug, or the compound is labeled with a detectable label or an affinity tag thereof. Also disclosed is a pharmaceutical composition, a method of treating a disorder mediated by melanocortin-4 receptors, and a method of treating obesity using the compounds described.Type: ApplicationFiled: March 26, 2015Publication date: July 16, 2015Inventors: Michel Bouvier, Anne Marinier, Réjean Ruel, Patricia René, Yves Chantigny, Philippe Dagneau, Stéphane Gingras
-
Publication number: 20150150224Abstract: There are provided herein transgenic non-human animals and cells comprising a transgene encoding either a mutated human melanocortin type-4 receptor (hMC4R) protein, wherein the mutated protein is misfolded and retained intracellularly, or a wild-type human melanocortin type-4 receptor (hMC4R) protein. Transgenes and targeting constructs used to produce such transgenic animals and cells are also provided, as well as methods for using the transgenic animals in pharmaceutical screening and as commercial research animals for modeling obesity.Type: ApplicationFiled: June 14, 2013Publication date: June 4, 2015Applicant: UNIVERSITE DE MONTREALInventors: Michel Bouvier, Patricia Rene, Benjamin Turgeon
-
Patent number: 9018395Abstract: Disclosed herein is a compound of Formula I: wherein X, R1, R2, and R3 are as defend herein, or a pharmaceutically acceptable salt thereof to allow the drug to penetrate the cell membrane; or a prodrug, or the compound is labeled with a detectable label or an affinity tag thereof. Also disclosed is a pharmaceutical composition, a method of treating a disorder mediated by melanocortin-4 receptors, and a method of treating obesity using the compounds described.Type: GrantFiled: January 26, 2012Date of Patent: April 28, 2015Assignee: Université de MontréalInventors: Michel Bouvier, Anne Marinier, Réjean Ruel, Patricia René, Yves Chantigny, Philippe Dagneau, Stéphane Gingras
-
Publication number: 20140057894Abstract: Disclosed herein is a compound of Formula I: wherein X, R1, R2, and R3 are as defend herein, or a pharmaceutically acceptable salt thereof to allow the drug to penetrate the cell membrane; or a prodrug, or the compound is labeled with a detectable label or an affinity tag thereof. Also disclosed is a pharmaceutical composition, a method of treating a disorder mediated by melanocortin-4 receptors, and a method of treating obesity using the compounds described.Type: ApplicationFiled: January 26, 2012Publication date: February 27, 2014Applicant: Universite De MontrealInventors: Michel Bouvier, Anne Marinier, Rejean Ruel, Patricia René, Yves Chantigny, Philippe Dagneau, Stéphane Gingras
-
Publication number: 20130165426Abstract: Disclosed is a compound of Formula I or a salt thereof, in which X, X1, X2, R1, R2, and R3 are described herein. Also disclosed are pharmaceutical compositions and methods of using the compounds of Formula I to treat disorders mediated by melanocortin-4 receptors.Type: ApplicationFiled: July 5, 2011Publication date: June 27, 2013Applicant: UNIVERSITÉ DE MONTRÉALInventors: Réjean Ruel, Yves Chantigny, Anne Marinier, Patricia Rene, Michel Bouvier